In OC with BRCA1/2 mutations, the tumor load is increased and TILs are increased; furthermore, PD1/PD-L1 expression is upregulated in response to multiple interferon γ, P53 and BRCA mutations, thus possibly leading to greater sensitivity to PD1/PD-1 inhibitors (Jiang et al., 2021). This evidence concerns the gene CD274 and neoplasm.